Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | PLD2 | O14939 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014333 | 1.00 | RXFP1 (0.47) | RXFP1MAPTP2RX1GPR35PLD2 | |
| SCHEMBL12097686 | 0.89 | P2RY14 (0.48) | RXFP1MAPTP2RX1GPR35SLC13A3 | |
| SCHEMBL8574413 | 0.88 | MAPT (0.57) | RXFP1MAPTP2RX1GPR35SLC13A3 | |
| SCHEMBL30559781 | 0.88 | RXFP1 (0.40) | RXFP1MAPTPLD2PLD1CYP17A1 | |
| SCHEMBL30559778 | 0.88 | RXFP1 (0.40) | RXFP1MAPTPLD2PLD1CYP17A1 | |
| SCHEMBL24355541 | 0.88 | RXFP1 (0.40) | RXFP1MAPTPLD2PLD1CYP17A1 | |
| SCHEMBL12097475 | 0.87 | NOTUM (0.55) | RXFP1MAPTP2RX1GPR35SLC13A3 | |
| SCHEMBL13996788 | 0.82 | MAPT (0.51) | RXFP1MAPTP2RX1GPR35SLC13A3 | |
| SCHEMBL29905046 | 0.82 | RXFP1 (0.42) | RXFP1MAPTP2RX1GPR35SLC13A3 | |
| SCHEMBL8572362 | 0.81 | SLC13A3 (0.63) | RXFP1MAPTP2RX1GPR35SLC13A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232108-B | SOS1 degradation agent and preparation method and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-1482940-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1448534-A1 | 6-MEMBERED UNSATURATED HETEROCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OFTHE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
| WO-2003028729-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003029224-A1 | 6-MEMBERED UNSATURATED HETEROCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, PLG | RXFP1 2913/4885MAPT 4848/4885P2RX1 3664/4885 |
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, TFPI2 | RXFP1 3348/4885MAPT 4840/4885P2RX1 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.